Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: A prospective study

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 6, 2000, Pages 745-750

  Graham, D Y ^a,b   Osato, M S ^a   Hoffman, J ^a   Opekun, A R ^a   Anderson, S Y ^a   Kwon, D H ^a   El Zimaity, H M T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH SALICYLATE; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; FLATULENCE; GRAM NEGATIVE INFECTION; HAIR LOSS; HEADACHE; HEART PALPITATION; HELICOBACTER PYLORI; HUMAN; MALAISE; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMEMBRANOUS COLITIS; SLEEP DISORDER; TASTE DISORDER; TREATMENT FAILURE; UNITED STATES; VAGINA CANDIDIASIS; VERTIGO; VOMITING;

AGED; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; SALICYLATES; TETRACYCLINE; TREATMENT OUTCOME;

EID: 0034113158     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00770.x     Document Type: Article

References (49)

1. 1 Graham DY, Dore MP. Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis. In: Hunt RH, Tytgat GNJ, eds. Helicobacter Pylori Basic Mechanisms to Clinical Cure. Dordrecht: Kluwer Academic Publishers, 1998: 426-40.
2. 2 Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115: 1272-7.
3. 3 Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998; 115: 1278-82.
4. 4 Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997; 11(Suppl. 1): 43-53.
5. 5 Midolo PD, Korman MG, Turnidge JD, Lambert JR. Helicobacter pylori resistance to tetracycline. Lancet 1996; 347: 1194-5(Letter).
6. 6 Dore MP, Piana A, Carta M, Atzei A, et al. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 635-9.
7. 7 Realdi G, Dore MP, Piana A, Atzei A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999; 4: 106-12.
8. 8 van Zwet AA, Vandenbrouke-Grauls CM, Thijs JC, van der Wouden EJ, et al. Stable amoxicillin resistance in Helicobacter pylori. Lancet 1998; 352: 1595(Letter).
9. 9 Graham DY, Lew GM, Evans DG, Evans DJ Jr, et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med 1991; 115: 266-9.
10. 10 Borody TJ, Cole P, Noonan S, Morgan A, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151: 431-5.
11. 11 van der Hulst RWM, Keller JJ, Rauws EA, Tytgat GNJ. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter 1996; 1: 6-19.
12. 12 Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2330-8.
13. 13 Borody TJ, Andrews P, Fracchia G, Brandl S, et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37: 477-81.
14. 14 Kung NN, Sung JJ, Yuen NW, Ng PW, et al. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy. Am J Gastroenterol 1997; 92: 438-41.
15. 15 Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999; 94: 725-9.
16. 16 de Boer WA, Haeck PW, Otten MH, Mulder CJ. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. Am J Gastroenterol 1998; 93: 1101-7.
17. 17 de Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J Clin Gastroenterol 1996; 22: 313-6.
18. 18 van der Hulst RW, van der Ende A, Homan A, Roorda P, et al. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 1998; 42: 166-9.
19. 19 de Boer WA, Etten RJ, Lai JY, Schneeberger PM, et al. Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. Helicobacter 1996; 1: 145-50.
20. 20 Graham DY, Hoffman J, El-Zimaity HM, Graham DP, et al. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 935-8.
21. 21 El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. Hum Pathol 1999; 30: 72-7.
22. 22 El-Zimaity HM, Al-Assi MT, Genta RM, Graham DY. Confirmation of successful therapy of Helicobacter pylori infection: number and site of biopsies or a rapid urease test. Am J Gastroenterol 1995; 90: 1962-4.
23. 23 Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. Hum Pathol 1994; 25: 221-6.
24. 24 El-Zimaity HM, Ota H, Scott S, Killen DE, et al. A new triple stain for Helicobacter pylori suitable for the autostainer: carbol fuchsin/Alcian blue/hematoxylin-eosin. Arch Pathol Lab Med 1998; 122: 732-6.
25. 25 de Boer WA, Thys JC, Borody TJ, Graham DY, et al. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol 1996; 8: 641-3.
26. 26 Pagan T. Quickbasic program for exact and mid-P confidence intervals for a binomial proportion. Comput Biol Med 1996; 26: 263-7.
27. 27 National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Sixth informational supplement M100S9 19, 1. Villanova, PA: National Committee for Clinical Laboratory Standards, 1999.
28. 28 Versalovic J, Osato MS, Spakovsky K, Dore MP, et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 1997; 40: 283-6.
29. 29 Stone GG, Shortridge D, Flamm RK, Versalovic J, et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter 1996; 1: 227-8.
30. 30 Versalovic J, Shortridge D, Kibler K, Griffy MV, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-80.
31. 31 Declerck PJ, De Ranter CJ. In vitro reductive activation of nitroimidazoles. Biochem Pharmacol 1986; 35: 59-61.
32. 32 Declerck PJ, De Ranter CJ, Volckaert G. Base specific interaction of reductively activated nitroimidazoles with DNA. FEBS Lett 1983; 164: 145-8.
33. 33 Koch-Weser J, Goldman P. Drug therapy: metronidazole. N Engl J Med 1980; 303: 1212-8.
34. 34 Edwards DI. Nitroimidazole drugs - action and resistance mechanisms. I. Mechanisms action. J Antimicrob Chemother 1993; 31: 9-20.
35. 35 Edwards DI. Nitroimidazole drugs - action and resistance mechanisms. II. Mechanisms resistance. J Antimicrob Chemother 1993; 31: 201-10.
36. 36 Lockerby DL, Rabin HR, Laishley EJ. Role of the phosphoroclastic reaction of Clostridium pasteurianum in the reduction of metronidazole. Antimicrob Agents Chemother 1985; 27: 863-7.
37. 37 Edwards DI, Dye M, Carne H. The selective toxicity of antimicrobial nitroheterocyclic drugs. J Gen Microbiol 1973; 76: 135-45.
38. 38 Lindmark DG, Muller M. Antitrichomonad action, mutagenicity, and reduction of metronidazole and other nitroimidazoles. Antimicrob Agents Chemother 1976; 10: 476-82.
39. 39 Kedderis GL, Argenbright LS, Miwa GT. Mechanism of reductive activation of a 5-nitroimidazole by flavoproteins: model studies with dithionite. Arch Biochem Biophys 1988; 262: 40-8.
40. 40 Muller M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surg 1983; 93: 165-71.
41. 41 Perez-Reyes E, Kalyanaraman B, Mason RP. The reductive metabolism of metronidazole and ronidazole by aerobic liver microsomes. Mol Pharmacol 1980; 17: 239-44.
42. 42 Sealy RC, Swartz HM, Olive PL. Electron spin resonance-spin trapping. Detection of superoxide formation during aerobic microsomal reduction of nitro-compounds. Biochem Biophys Res Commun 1978; 82: 680-4.
43. 43 Al-Assi MT, Genta RM, Graham DY. Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1994; 8: 259-62.
44. 44 Graham DY, Evans DG. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers. Rev Infect Dis 1990; 12(Suppl. 1): S68-72.
45. 45 de Boer WA. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999; 11: 697-700.
46. 46 Dore MP, Leandro G, Realdi G, Sepulveda A, et al. The effect of pre-treatment antibiotic resistance to metronidazole or clarithromycin on the outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 68-76.
47. 47 Ducons JA, Santolaria S, Guirao R, Ferrero M, et al. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 1999; 13: 775-80.
48. 48 Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000; 118: 52-58.
49. 49 van der Wouden EJ, van Thijs JC, Zwet AA, Sluiter WJ, et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-9.